Loading stock data…
GRFS
$8.23-0.01 (-0.12%)
Market ClosedLast close May 1
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grifols, S.A. in the Healthcare sector is trading at $8.23. The stock is currently 26% below its 52-week high of $11.14, remaining 10.3% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why GRFS maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.23
Potential Upside
67.8%
Whystock Fair Value$13.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.44B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.41
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.07%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.75%
Volume
Today's trading volume
137,929
Recent News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini
Is Grifols (BME:GRF) A Potential Opportunity After A 59% Five Year Share Price Slide
If you are wondering whether Grifols at around €8.95 is a bargain or a value trap, you are not alone. The stock has been volatile, with a 4.5% decline over the past week, a 2.5% gain over the last month, a 20.1% decline year to date, a 6.5% return over the last year, and a 59.4% decline over five years. These swings have kept Grifols in the spotlight, as investors reassess both its long term prospects and the risks that might be priced into the shares. Recent coverage has focused on how...
Grifols (GRFS) Unveils AI-Driven Data for Early Parkinson’s Disease Detection
Grifols (NASDAQ:GRFS) is one of the 10 Overlooked Growth Stocks to Buy Now. Grifols (NASDAQ:GRFS) is one of the overlooked growth stocks to buy now. On March 17, Grifols unveiled proof-of-concept data from its Chronos-PD program, showing that molecular changes associated with Parkinson’s disease/PD can be detected up to 12 years before a clinical diagnosis. […]
Health Canada Imposes New Conditions on Grifols, S.A. (GRFS) Plasma Collection Centers
We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Grifols, S.A. is one of the best healthcare stocks on this list. TheFly reported on April 2 that CBC News reported that Health Canada introduced new regulatory conditions on GRFS’ paid plasma collection centers nationwide after repeated […]
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.